FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news